The FDA is expected to decide on treatments for COPD, psoriasis, rare neuroendocrine tumors, and a next-generation COVID-19 vaccine.

(HKEX: 02162)�("Keymed" or the "Company") today announced that the prestigious medical journal Nature Medicine has published the results from the Phase III trial of its independently developed�IL-4Ra ...

The following is a summary of “Intrathecal interleukin-6 levels are associated with progressive disease and clinical severity ...

Wounds healed twice as fast compared to standard treatments, the researchers revealed. While most microneedle tech focuses on ...